Shares of Interpace Diagnostics Group Inc (NASDAQ:IDXG) have been assigned a consensus recommendation of “Buy” from the six brokerages that are covering the firm, MarketBeat.com reports. Two analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $3.56.
Several research analysts recently weighed in on IDXG shares. HC Wainwright set a $4.00 target price on shares of Interpace Diagnostics Group and gave the company a “buy” rating in a research note on Tuesday. Maxim Group reissued a “buy” rating and issued a $4.00 target price on shares of Interpace Diagnostics Group in a research note on Wednesday, March 20th.
Shares of IDXG stock opened at $0.71 on Monday. Interpace Diagnostics Group has a twelve month low of $0.67 and a twelve month high of $1.78. The stock has a market capitalization of $27.44 million, a P/E ratio of -1.65 and a beta of 2.50.
Interpace Diagnostics Group (NASDAQ:IDXG) last announced its earnings results on Monday, May 13th. The business services provider reported ($0.10) earnings per share for the quarter, missing the consensus estimate of ($0.07) by ($0.03). Interpace Diagnostics Group had a negative net margin of 53.75% and a negative return on equity of 34.67%. The firm had revenue of $6.01 million during the quarter, compared to analyst estimates of $6.10 million. Equities analysts expect that Interpace Diagnostics Group will post -0.21 earnings per share for the current fiscal year.
A number of hedge funds have recently made changes to their positions in IDXG. Sio Capital Management LLC acquired a new position in Interpace Diagnostics Group in the 1st quarter valued at about $1,322,000. Perkins Capital Management Inc. grew its holdings in Interpace Diagnostics Group by 86.4% in the 1st quarter. Perkins Capital Management Inc. now owns 1,922,250 shares of the business services provider’s stock valued at $1,538,000 after buying an additional 891,250 shares during the period. JPMorgan Chase & Co. purchased a new stake in Interpace Diagnostics Group in the 3rd quarter valued at about $194,000. Essex Investment Management Co. LLC grew its holdings in Interpace Diagnostics Group by 12.4% in the 4th quarter. Essex Investment Management Co. LLC now owns 339,678 shares of the business services provider’s stock valued at $272,000 after buying an additional 37,506 shares during the period. Finally, Northern Trust Corp grew its holdings in Interpace Diagnostics Group by 27.4% in the 1st quarter. Northern Trust Corp now owns 88,246 shares of the business services provider’s stock valued at $70,000 after buying an additional 19,001 shares during the period. 14.40% of the stock is owned by hedge funds and other institutional investors.
About Interpace Diagnostics Group
Interpace Diagnostics Group, Inc develops and commercializes molecular diagnostic tests to detect genetic and other molecular alterations associated with gastrointestinal and endocrine cancers. It offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion molecular test that helps physicians better assess risk of pancreaticobiliary cancers using its proprietary PathFinder platform; ThyGenX, an oncogenic mutation panel that helps identify malignant thyroid nodules; and ThyraMIR, an microRNA gene expression assay that helps to classify risk of cancer in thyroid nodules.
See Also: Index Funds
Receive News & Ratings for Interpace Diagnostics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Interpace Diagnostics Group and related companies with MarketBeat.com's FREE daily email newsletter.